Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study

Glucagon-like peptide-1 receptor agonists (GLP-1RA) are widely prescribed for Type 2 diabetes and obesity owing to their robust metabolic and cardiovascular benefits.Emerging reports, however, suggest a potential link between GLP-1RA use and non-scarring hair loss (NSHL), including telogen effluvium (TE), androgenic alopecia (AGA), and alopecia areata (AA).To clarify this association, the authors conducted the first large-scale, real-world multicentre cohort study evaluating GLP-1RA exposure and risk of hair loss (HL). 1